Free Trial
NASDAQ:MIST

Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis

Milestone Pharmaceuticals logo
$1.43 -0.02 (-1.38%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.46 +0.03 (+1.75%)
As of 08/1/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Milestone Pharmaceuticals Stock (NASDAQ:MIST)

Key Stats

Today's Range
$1.40
$1.48
50-Day Range
$1.38
$2.56
52-Week Range
$0.63
$2.75
Volume
671,601 shs
Average Volume
2.82 million shs
Market Capitalization
$76.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Hold

Company Overview

Milestone Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

MIST MarketRank™: 

Milestone Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat, and ranked 709th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Milestone Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Milestone Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Milestone Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($0.62) to ($1.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Milestone Pharmaceuticals is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Milestone Pharmaceuticals is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Milestone Pharmaceuticals has a P/B Ratio of 5.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Milestone Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.58% of the outstanding shares of Milestone Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Milestone Pharmaceuticals has recently increased by 159.90%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Milestone Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Milestone Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.58% of the outstanding shares of Milestone Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Milestone Pharmaceuticals has recently increased by 159.90%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Milestone Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Milestone Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    7 people have searched for MIST on MarketBeat in the last 30 days.
  • MarketBeat Follows

    7 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.50% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Milestone Pharmaceuticals' insider trading history.
Receive MIST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIST Stock News Headlines

Is America’s Everything Bubble About to Burst?
On July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushing America’s debt-to-GDP ratio to 175%. Top investors are warning of an epic bubble bursting soon. A free guide reveals how to shield your 401(k), savings, and portfolio before the collapse.
See More Headlines

MIST Stock Analysis - Frequently Asked Questions

Milestone Pharmaceuticals' stock was trading at $2.36 on January 1st, 2025. Since then, MIST shares have decreased by 39.4% and is now trading at $1.43.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) issued its earnings results on Wednesday, May, 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.12.

Milestone Pharmaceuticals (MIST) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Top institutional shareholders of Milestone Pharmaceuticals include Valeo Financial Advisors LLC (0.24%) and Bay Rivers Group (0.03%). Insiders that own company stock include Rtw Investments, Lp, Robert James Wills, David Bharucha and Debra K Liebert.
View institutional ownership trends
.

Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Tilray Brands (TLRY), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), Vaxart (VXRT) and Aquestive Therapeutics (AQST).

Company Calendar

Last Earnings
5/14/2025
Today
8/02/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MIST
CIK
1408443
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$5.00
Potential Upside/Downside
+389.5%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$41.52 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-329.85%
Return on Assets
-67.20%

Debt

Debt-to-Equity Ratio
4.06
Current Ratio
4.67
Quick Ratio
4.67

Sales & Book Value

Annual Sales
$1 million
Price / Sales
76.45
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.25 per share
Price / Book
5.72

Miscellaneous

Outstanding Shares
53,460,000
Free Float
43,039,000
Market Cap
$76.45 million
Optionable
Optionable
Beta
0.52

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:MIST) was last updated on 8/3/2025 by MarketBeat.com Staff
From Our Partners